ABCL vs. MNKD, PRTA, MIRM, BLTE, SYRE, COLL, IRWD, PCRX, GMTX, and LQDA
Should you be buying AbCellera Biologics stock or one of its competitors? The main competitors of AbCellera Biologics include MannKind (MNKD), Prothena (PRTA), Mirum Pharmaceuticals (MIRM), Belite Bio (BLTE), Spyre Therapeutics (SYRE), Collegium Pharmaceutical (COLL), Ironwood Pharmaceuticals (IRWD), Pacira BioSciences (PCRX), Gemini Therapeutics (GMTX), and Liquidia (LQDA). These companies are all part of the "pharmaceutical preparations" industry.
MannKind (NASDAQ:MNKD) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, community ranking, risk, analyst recommendations and valuation.
MannKind presently has a consensus target price of $8.00, indicating a potential upside of 83.49%. AbCellera Biologics has a consensus target price of $16.17, indicating a potential upside of 310.32%. Given MannKind's higher possible upside, analysts plainly believe AbCellera Biologics is more favorable than MannKind.
49.5% of MannKind shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 3.0% of MannKind shares are owned by company insiders. Comparatively, 32.5% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
MannKind has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500.
MannKind has a net margin of -6.00% compared to MannKind's net margin of -384.99%. AbCellera Biologics' return on equity of 0.00% beat MannKind's return on equity.
In the previous week, AbCellera Biologics had 5 more articles in the media than MannKind. MarketBeat recorded 15 mentions for AbCellera Biologics and 10 mentions for MannKind. AbCellera Biologics' average media sentiment score of 0.63 beat MannKind's score of -0.07 indicating that MannKind is being referred to more favorably in the media.
MannKind has higher revenue and earnings than AbCellera Biologics. MannKind is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.
MannKind received 522 more outperform votes than AbCellera Biologics when rated by MarketBeat users. However, 77.27% of users gave AbCellera Biologics an outperform vote while only 59.87% of users gave MannKind an outperform vote.
Summary
MannKind beats AbCellera Biologics on 9 of the 17 factors compared between the two stocks.
Get AbCellera Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AbCellera Biologics Competitors List
Related Companies and Tools
